DEA Cannabis Rescheduling: Post-Hearing Briefs Are Due August 17 — What Happens Next?

DEA cannabis rescheduling 2026 is entering its final administrative phase. Post-hearing briefs are due August 17, 2026 — and what happens next will shape the federal legal status of cannabis for years to come. Here is what you need to know about the process, the players, the timeline, and what it all means if you are a cannabis consumer in DC, Maryland, or Virginia.

A Quick Recap: Where the DEA Rescheduling Process Stands

On April 23, 2026, the Acting Attorney General signed a final order moving two categories of cannabis from Schedule I to Schedule III of the Controlled Substances Act: FDA-approved cannabis drug products and state-licensed medical marijuana. That order took effect immediately, making it the most significant shift in federal cannabis law in decades.

But that order did not cover adult-use cannabis. To address the broader question of whether all marijuana should move to Schedule III, the DEA convened a formal administrative law hearing. That hearing ran from June 29 to July 15, 2026, at DEA headquarters in Arlington, Virginia. Chief Administrative Law Judge (ALJ) Derek C. Julius presided.

The evidentiary portion is now complete. Parties were presented with the opportunity to submit post-hearing briefs by August 17, 2026 — and those briefs represent the final input before the ALJ writes his recommendation.

For more background on the hearing itself and what was argued, read our companion piece: Federal Cannabis Rescheduling: Schedule III Hearing and Post-Briefs 2026.

What Are Post-Hearing Briefs, and Why Do They Matter?

Think of post-hearing briefs as written closing arguments. Because ALJ Julius did not allot time for oral closing statements during the live hearing sessions, participating parties were invited to submit written briefs — up to 50 pages each — laying out their final positions on the evidence and the legal questions before the tribunal.

Submission is voluntary, not mandatory. But virtually every major party is expected to file. The parties include:

• Smart Approaches to Marijuana (SAM) — the leading anti-rescheduling advocacy group

• The National Drug and Alcohol Screening Association (NDASA)

• State attorneys general who intervened in the proceedings

• Dr. Finn and other expert witnesses who testified during the hearing

• The DEA and Department of Justice themselves

It is worth noting that the parties selected to participate in this hearing were predominantly opponents of rescheduling. Cannabis advocates and pro-rescheduling groups largely had their participation requests denied, a point that drew sharp criticism from industry stakeholders and civil liberties organizations throughout the process.

What Happens After August 17?

Once the August 17 deadline passes, the process moves through three more stages before any final rule can take effect.

Stage 1: Transcript Finalization

Along with their briefs, parties may submit proposed corrections to the official hearing transcript. ALJ Julius will review those corrections and finalize the transcript, which will then be posted publicly on the DEA's website. This creates the official administrative record.

Stage 2: ALJ Recommended Decision

After reviewing all the briefs and the full evidentiary record, Judge Julius will draft a recommended decision for the DEA Administrator. There is no statutory deadline for this step. Observers expect the ALJ recommendation to arrive sometime in late 2026, though there is no guarantee of that timeline. It is important to understand that this is a recommendation, not a final ruling. The ALJ advises; the Administrator decides.

Stage 3: DEA Administrator Final Determination

Once the record transfers to DEA Administrator Terry Cole, she holds the final authority to issue the rule that changes the federal schedule for cannabis. She may accept, reject, or modify the ALJ's recommendation. This step is where the political and policy dimensions of rescheduling will ultimately play out. A final determination in 2027 is a realistic scenario given the pace of federal administrative proceedings.

The Parallel Legal Battle: SAM v. DOJ in the D.C. Circuit

The administrative hearing is not the only legal proceeding worth tracking. A separate federal lawsuit — SAM Inc. v. U.S. Department of Justice, Case Nos. 26-1106 and 26-1130 — is pending in the D.C. Circuit Court of Appeals. That case challenges the April 23 Final Order directly, arguing the Attorney General exceeded his authority by bypassing notice-and-comment procedures.

As of August 9, 2026, the motion for a stay pending review is fully briefed. Petitioners filed their reply brief on July 16, and the court is now weighing whether to freeze the rescheduling order while the full case proceeds. No ruling has been issued yet.

This is a separate track from the DEA administrative process. The D.C. Circuit case could theoretically reverse or pause the April 23 order that already moved medical cannabis to Schedule III. The DEA administrative hearing is about whether adult-use cannabis should follow. Both matter, and both remain unresolved.

For a deeper breakdown of the court case, read: SAM v. DOJ: The Cannabis Rescheduling Lawsuit in the D.C. Circuit.

What Schedule III Actually Means — and What It Does Not

There is a lot of confusion about what moving cannabis to Schedule III would actually change. Here is a plain-language breakdown.

The 280E Tax Burden

Under Schedule I, cannabis businesses are blocked from deducting ordinary business expenses under IRS Section 280E. This can push effective federal tax rates for cannabis operators to nearly 70 percent. Moving to Schedule III removes this penalty — a change that could save the industry over $2 billion annually. Medical cannabis businesses already received this relief under the April 23 order. Adult-use operators are still waiting.

Banking Access

Rescheduling has not automatically solved cannabis banking. Financial institutions still operate under the Bank Secrecy Act and FinCEN's 2014 guidance for marijuana-related businesses. However, the lower federal risk designation has encouraged more banks and credit unions to work with medical operators. The SAFE Banking Act of 2026 was reintroduced in June to formalize those protections, but it remains stalled in Congress.

Research Access

Schedule III status has created an expedited registration pathway for researchers working with cannabis. Academic institutions can now study state-licensed medical products without risking federal funding, and researchers are no longer limited to a single federally-approved source for cannabis. This is one of the most concrete near-term benefits of the current partial rescheduling.

What Does Not Change

Schedule III does not legalize cannabis at the federal level. Possession, distribution, and manufacture without authorization would still be federal crimes. It does not change DOT drug testing rules or most private employer drug-free workplace policies. It does not permit interstate cannabis commerce. It does not immediately lower prices at dispensaries. What it does is reduce the regulatory and tax burden on operators and recognize cannabis's accepted medical use at the federal level — a meaningful but limited shift.

What This Means for DC, Maryland, and Virginia Consumers

The federal rescheduling process is playing out against a complicated DMV backdrop. Here is where each market stands.

Washington, D.C.

DC continues to operate under the Congressional "Harris Rider," which blocks the city from taxing and regulating adult-use cannabis sales. The self-certification medical program remains the primary legal access point for adults. Any adult 21 and older can self-certify online in minutes. The broader federal rescheduling process does not directly change DC's unique situation, since the Harris Rider is a Congressional appropriations matter — not a scheduling one. That said, a completed federal rescheduling could eventually reshape DC's legislative options.

Maryland

Maryland's adult-use market is fully operational. The April 23 Final Order already delivered 280E tax relief to Maryland's licensed medical operators, which may gradually affect product variety and pricing. A final rule covering adult-use cannabis could further reduce operator costs — but given the timeline, consumers should not expect any pricing impact from federal rescheduling before 2027 at the earliest.

Virginia

Virginia's adult-use retail launch is set for July 1, 2027. Federal rescheduling proceedings run on a completely separate track from that state-level timeline. Virginia's hemp THC crackdown — a 2mg cap per package taking effect August 15, 2026 — is also unrelated to the federal Schedule III process. For Virginia consumers, the biggest near-term change from federal rescheduling would be if the SAM v. DOJ stay motion succeeds and pauses the April 23 order affecting medical patients.

A Note on Uncertainty: This Is Not a Done Deal

Federal administrative proceedings rarely move quickly, and cannabis rescheduling has been contested at every step. The August 17 brief deadline is significant — it closes the evidentiary record and starts the clock on the ALJ recommendation — but it does not finalize anything. The ALJ recommendation carries no legal force on its own. The DEA Administrator retains full discretion. The D.C. Circuit court could issue a stay that pauses the existing April 23 order before any broader rule is finalized.

This article is for informational purposes only. Nothing here is legal or financial advice. The rescheduling process is ongoing and unresolved.

Stay Current on Federal Cannabis Law — and Shop What Is Legal Now

While the federal process plays out, DC, Maryland, and Virginia consumers have legal access to high-quality cannabis today. Bud Lords delivers directly to you across the DMV region. Browse our current selection at the Bud Lords shop and check the Bud Lords Cannabis Newsroom for ongoing coverage of the DEA rescheduling process, DMV market updates, and everything you need to know about cannabis in the region.

This article was researched and written with AI assistance by the Bud Lords AI Newsroom.